Natakalim improves post-infarction left ventricular remodeling by restoring the coordinated balance between endothelial function and cardiac hypertrophy

International Journal of Molecular Medicine

Volumn 34, Issue 5, 2014, Pages 1209-1218

  Zhou, Hong Min ^a   Zhong, Ming Li ^a   Zhang, Yan Fang ^a   Cui, Wen Yu ^b   Long, Chao Liang ^a   Wang, Hai ^a,b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Thadweik Academy of Medicine   (China)

Author keywords

Cardiac hypertrophy; Congestive heart failure; Endothelial function; Left ventricular remodelling; Myocardial infarction; Natakalim

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN 1; HYDROXYPROLINE; INDUCIBLE NITRIC OXIDE SYNTHASE; LISINOPRIL; NATAKALIM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POTASSIUM CHANNEL STIMULATING AGENT; PROSTACYCLIN; PROSTAGLANDIN F1 ALPHA; THROMBOXANE A2; THROMBOXANE B2; UNCLASSIFIED DRUG; ALLYL COMPOUND; ENDOTHELIN; PROPYLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BALANCE COORDINATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; DEPRESSED BLOOD PRESSURE; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL FUNCTION; GENE OVEREXPRESSION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE INFARCTION; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEMODYNAMICS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LUNG WEIGHT; MALE; MEAN ARTERIAL PRESSURE; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; MUSCLE FIBRIL; NONHUMAN; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; UPREGULATION; ANIMAL; BLOOD; BLOOD PRESSURE; CARDIOMEGALY; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; HEART FAILURE; HEART MUSCLE; HEART VENTRICLE; IMMUNOHISTOCHEMISTRY; METABOLISM; MYOCARDIAL INFARCTION; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR ENDOTHELIUM; WISTAR RAT;

ADMINISTRATION, ORAL; ALLYL COMPOUNDS; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELINS; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; HEART FAILURE; HEART VENTRICLES; HYDROXYPROLINE; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MYOCARDIAL INFARCTION; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NITRIC OXIDE; PROPYLAMINES; RATS; RATS, WISTAR; THROMBOXANE A2; VENTRICULAR REMODELING;

EID: 84907195231     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1931     Document Type: Article

References (39)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P and ESC Committee for Practice Guidelines: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33: 1787-1847, 2012.
2. Konstam MA, Kramer DG, Patel AR, Maron MS and Udelson JE: Left ventricular remodeling in heart failure: Current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 4: 98-108, 2011.
3. Lerman A and Zeiher AM: Endothelial function: Cardiac events. Circulation 111: 363-368, 2005.
4. Adamopoulos S, Parissis JT and Kremastinos DT: Endothelial dysfunction in chronic heart failure: Clinical and therapeutic implications. Eur J Intern Med 13: 233-239, 2002.
5. Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aretz HT, Lindsey ML, Vançon AC, Huang PL, Lee RT, Zapol WM and Picard MH: Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 104: 1286-1291, 2001.
6. Prasad A, Higano ST, Al Suwaidi J, Holmes DR Jr, Mathew V, Pumper G, Lennon RJ and Lerman A: Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction. Am Heart J 146: 549-554, 2003.
7. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS and Walsh K: Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115: 2108-2118, 2005.
8. Seino S and Miki T: Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol 81: 133-176, 2003.
9. Yoshida H, Feig JE, Morrissey A, Ghiu IA, Artman M and Coetzee WA: KATP channels of primary human coronary artery endothelial cells consist of a heteromultimeric complex of kir6.1, kir6.2, and sur2b subunits. J Mol Cell Cardiol 37: 857-869, 2004.
10. Nichols CG, Singh GK and Grange DK: KATP channels and cardiovascular disease: suddenly a syndrome. Circ Res 112: 1059-1072, 2013.
11. Gao S, Long CL, Wang RH and Wang H: KATP activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc Res 83: 444-456, 2009.
12. Tang Y, Long CL, Wang RH, Cui W and Wang H: Activation of SUR2B/Kir6.1 subtype of adenosine triphosphate-sensitive potassium channel improves pressure overload-induced cardiac remodeling via protecting endothelial function. J Cardiovasc Pharmacol 56: 345-353, 2010.
13. Chen Y, Pan Z, Cui W and Wang H: Selectivity of new iptakalim derivatives on the subtypes of ATP-sensitive potassium channels. Chin Pharmacol Bull 24: 1427-1430, 2008.
14. Wei H, Cao YQ, Zhang JD, Peng Z, Yang DF, Liu JY, Shi YP, Yang YL and Wang H: Protective effects of SUR2B/Kir6.1 potassium channel opener natakalim against RAVECs injuries induced by hypoxia. Chin J Appl Physiol 28: 241-244, 2012.
15. Goldman S and Raya TE: Rat infarct model of myocardial infarction and heart failure. J Card Fail 1: 169-177, 1995.
16. Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D'Agostino RB, Levy D, Kannel WB and Vasan RS: Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 118: 2057-2062, 2008.
17. Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC and McAlister FA: Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol 53: 13-20, 2009.
18. Krzemi-ski TF, Nozy-ski JK, Grzyb J and Porc M: Wide-spread myocardial remodeling after acute myocardial infarction in rat. Features for heart failure progression. Vascul Pharmacol 48: 100-108, 2008.
19. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA and Butler J: Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol 60: 1455-1469, 2012.
20. Khazaei M, Moien-Afshari F and Laher I: Vascular endothelial function in health and diseases. Pathophysiology 15: 49-67, 2008.
21. Yin WH, Chen YH, Wei J, Jen HL, Huang WP, Young MS, Chen DC and Liu PL: Associations between endothelin-1 and adiponectin in chronic heart failure. Cardiology 118: 207-216, 2011.
22. Francois H, Athirakul K, Howell D, Dash R, Mao L, Kim HS, Rockman HA, Fitzgerald GA, Koller BH and Coffman TM: Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2: 201-207, 2005.
23. Feng Q, Song W, Lu X, Hamilton JA, Lei M, Peng T and Yee SP: Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. Circulation 106: 873-879, 2002.
24. Janssens S, Pokreisz P, Schoonjans L, Pellens M, Vermeersch P, Tjwa M, Jans P, Scherrer-Crosbie M, Picard MH, Szelid Z, Gillijns H, Van de Werf F, Collen D and Bloch KD: Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 94: 1256-1262, 2004.
25. Takimoto Y, Aoyama T, Keyamura R, Shinoda E, Hattori R, Yui Y and Sasayama S: Differential expression of three types of nitric oxide synthase in both infarcted and non-infarcted left ventricles after myocardial infarction in the rat. Int J Cardiol 76: 135-145, 2000.
26. Liu YH, Carretero OA, Cingolani OH, Liao TD, Sun Y, Xu J, Li LY, Pagano PJ, Yang JJ and Yang XP: Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol 289: H2616-H2623, 2005.
27. Starling RC: Inducible nitric oxide synthase in severe human heart failure: impact of mechanical unloading. J Am Coll Cardiol 45: 1425-1427, 2005.
28. Tousoulis D, Charakida M and Stefanadis C: Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol 100: 347-353, 2005.
29. Zhao RJ and Wang H: Chemerin/ChemR23 signaling axis is involved in the endothelial protection by KATP channel opener iptakalim. Acta Pharmacol Sin 32: 573-580, 2011.
30. Kolettis TM, Barton M, Langleben D and Matsumura Y: Endothelin in coronary artery disease and myocardial infarction. Cardiol Rev 21: 249-256, 2013.
31. Böhm F and Pernow J: The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 76: 8-18, 2007.
32. Spieker LE, Noll G, Ruschitzka FT and Lüscher TF: Endothelin receptor antagonists in congestive heart failure: A new therapeutic principle for the future? J Am Coll Cardiol 37: 1493-1505, 2001.
33. Nguyen QT, Cernacek P, Sirois MG, Calderone A, Lapointe N, Stewart DJ and Rouleau JL: Long-term effects of nonselective endothelin A and B receptor antagonism in postinfarction rat: importance of timing. Circulation 104: 2075-2081, 2001.
34. Harding P and Murray DB: The contribution of prostaglandins versus prostacyclin in ventricular remodeling during heart failure. Life Sci 89: 671-676, 2011.
35. Xiao CY, Hara A, Yuhki K, Fujino T, Ma H, Okada Y, Takahata O, Yamada T, Murata T, Narumiya S and Ushikubi F: Roles of prostaglandin I2 and thromboxane A2 in cardiac ischemia-reperfusion injury: A study using mice lacking their respective receptors. Circulation 104: 2210-2015, 2001.
36. Chan EC, Dusting GJ, Guo N, Peshavariya HM, Taylor CJ, Dilley R, Narumiya S and Jiang F: Prostacyclin receptor suppresses cardiac fibrosis: role of CREB phosphorylation. J Mol Cell Cardiol 49: 176-185, 2010.
37. Yuhki K, Kojima F, Kashiwagi H, Kawabe J, Fujino T, Narumiya S and Ushikubi F: Roles of prostanoids in the pathogenesis of cardiovascular diseases: novel insights from knockout mouse studies. Pharmacol Ther 129: 195-205, 2011.
38. Minamino T and Hori M: Protecting endothelial function: A novel therapeutic target of atp-sensitive potassium channel openers. Cardiovasc Res 73: 448-449, 2007.
39. Wang H, Tang Y, Wang L, Long CL and Zhang YL: ATP-sensitive potassium channel openers and 2,3-dimethyl-2-butylamine derivatives. Curr Med Chem 14: 133-155, 2007.